26 November 2021
Federal Council wants to revise rules on mail-order sales of non-prescription medicines
The regulation on mail-order sales of non-prescription medicinal products should be simplified, while ensuring patient safety. At its meeting of 24 November 2021, the Federal Council approved the report in fulfilment of the Stahl postulate. A consultation on the amendment of the Therapeutic Products Act (TPA) is planned until the beginning of 2023.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar